NEW YORK (Reuters Health) - While high levels of a tumor protein called Ki-67 are associated with worse breast cancer survival, they are not helpful in determining whether patients should receive chemotherapy in addition to estrogen-blocking drugs like tamoxifen, according to a brief report.